10-Q: TriSalus Life Sciences Reports 59.7% Revenue Growth in Q2 2024, Driven by TriNav Sales

TriSalus Life Sciences, Inc. reported a significant 59.7% increase in revenue for the second quarter of 2024, primarily attributed to strong sales of its TriNav Infusion System, despite facing challenges in its clinical development programs.

Summary

• TriSalus Life Sciences, Inc. reported a 59.7% increase in revenue for Q2 2024 compared to Q2 2023, totaling $7.4 million, driven by a $2.8 million increase in TriNav sales.
• Gross profit for Q2 2024 increased by 68.0% to $6.5 million, with gross margin improving to 87.6% from 83.3% in Q2 2023, due to increased manufacturing efficiencies and higher production volumes.
• Research and development expenses decreased by 32.2% to $4.7 million in Q2 2024, primarily due to a $2.2 million reduction in clinical trial expenses related to nelitolimod.
• Sales and marketing expenses increased by 71.9% to $6.0 million in Q2 2024, driven by higher payroll, travel expenses, and increased consulting and professional fees.
• General and administrative expenses decreased by 19.2% to $4.0 million in Q2 2024, mainly due to non-recurring expenses related to the Business Combination in the prior year.
• The company reported a net loss of $4.3 million for Q2 2024, an improvement from a net loss of $14.0 million in Q2 2023.
• For the six months ended June 30, 2024, revenue increased by 82.0% to $13.8 million, compared to $7.6 million in the same period in 2023.
• The company raised $6.7 million through the sale of 750,000 shares of common stock under the SEPA during the six months ended June 30, 2024.
• In April 2024, TriSalus entered into a credit agreement with OrbiMed for up to $50.0 million in senior secured term debt, drawing $25.0 million initially.
• The company is planning to unveil the DELIVER program, a series of clinical trials to evaluate the use of the TriNav system across diverse patient populations.
• As of June 30, 2024, TriSalus had cash and cash equivalents of $16.5 million and an accumulated deficit of $265.9 million.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the company's ongoing losses, the need for additional capital, and the identified material weaknesses in internal controls. However, the significant revenue growth, the potential of the TriNav technology, and the progress in securing financing provide some positive aspects.

Positives

• Revenue growth of 59.7% in Q2 2024, driven by increased TriNav sales.
• Gross profit margin improvement to 87.6% in Q2 2024, up from 83.3% in Q2 2023.
• Successful capital raise of $6.7 million through the SEPA in the first half of 2024.
• Secured up to $50.0 million in debt financing through a credit agreement with OrbiMed.
• CMS granted a New Technology HCPCS code for TriNav, potentially improving reimbursement prospects.
• The company is expanding its clinical trial program with the planned DELIVER initiative.
• The company successfully exchanged a significant portion of its outstanding Public Warrants and Private Placement Warrants for shares of common stock, reducing potential dilution.

Negatives

• The company reported a net loss of $4.3 million in Q2 2024 and $17.6 million for the six months ended June 30, 2024.
• Accumulated deficit of $265.9 million as of June 30, 2024.
• Sales and marketing expenses increased significantly due to higher payroll, travel, and consulting costs.
• The company faces challenges in its clinical development programs, particularly with nelitolimod.
• The company is still in its early stage and has yet to generate revenues sufficient to create positive cash flow.
• The company expects that its existing cash and cash equivalents will not be sufficient to fund projected liquidity requirements for the next 12 months.
• The company's management has identified material weaknesses in its internal control over financial reporting.

Risks

• The company has a limited operating history and has incurred significant losses since its inception.
• The company may not be able to generate sufficient cash to service its indebtedness or borrow additional funds pursuant to its Loan Facility.
• The company is highly dependent on the success of its TriNav device, and failure to achieve continued market acceptance will harm its business.
• The company faces intense competition in the biopharmaceutical and medical device industries.
• The company is subject to numerous complex regulatory requirements, and failure to comply may harm its business.
• The complexity of combination products presents additional development and regulatory challenges.
• Failure to obtain, protect, maintain or enforce intellectual property rights could harm the business.
• The company may experience difficulties in patient enrollment in clinical trials.
• The company may not be able to maintain the listing of its securities on Nasdaq.
• The company may not be able to adequately develop and implement the governance, compliance, risk management and control infrastructure and culture required for a public company.

Future Outlook

The company expects that its existing cash and cash equivalents will not be sufficient to fund its projected liquidity requirements for the next 12 months from the issuance date of the financial statements. If the company is able to achieve certain targets specified in the Credit Agreement and is then able to draw the remainder of the funds available, and if market conditions allow the company to sell additional shares under the SEPA, the company believes it can fund its operations through the end of 2025.

Industry Context

TriSalus operates in the highly competitive biotechnology and medical device industries, focusing on developing innovative drug delivery technologies for treating liver and pancreatic cancers. The company's focus on interventional radiology and immuno-oncology places it at the intersection of these two rapidly evolving fields. The industry is characterized by intense competition, rapid technological advancements, and significant regulatory hurdles.

Comparison to Industry Standards

• Compared to industry standards, TriSalus' revenue growth of 59.7% in Q2 2024 is significant. For example, Boston Scientific, a major medical device company, reported revenue growth of 13.7% in Q2 2024. However, TriSalus' revenue base is much smaller.
• TriSalus' gross margin of 87.6% in Q2 2024 is higher than many medical device companies. For instance, Medtronic reported a gross margin of 65.8% in its most recent quarter.
• TriSalus' focus on developing a novel drug delivery system for solid tumors is unique, but other companies like Delcath Systems are also pursuing regional drug delivery approaches for liver cancers.
• TriSalus' net loss is not unusual for a clinical-stage biotechnology company. Many companies in this stage invest heavily in R&D and may not generate significant revenue for several years. For example, Immunocore Holdings plc, a company developing immunotherapies for cancer, reported a net loss of $28.7 million in Q2 2024.
• Compared to other companies developing TLR9 agonists, such as Dynavax Technologies, TriSalus is in an earlier stage of clinical development for nelitolimod.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises and warrant exercises. Stock price may be volatile due to market conditions and company performance.
• Employees: The company's growth strategy may create job opportunities, but financial challenges could impact job security.
• Customers: Continued development and commercialization of TriNav could provide new treatment options for patients with liver and pancreatic cancers.
• Suppliers: The company's reliance on a limited number of suppliers for certain materials could create risks for both the company and its suppliers.
• Creditors: The company's ability to service its debt obligations depends on its future financial performance and ability to raise additional capital.

Next Steps

• The company plans to continue to invest in the commercialization of TriNav.
• The company will continue clinical trials and other development, manufacturing, and regulatory activities for TriNav and nelitolimod.
• The company will seek to raise additional capital through a combination of collaborations, strategic alliances, licensing arrangements, and issuance of additional equity and/or debt.
• The company will continue to implement its remediation plan to address the material weaknesses in internal control over financial reporting.
• The company plans to unveil the DELIVER program, a series of clinical trials to evaluate the use of the TriNav system across diverse patient populations.

Key Dates

Keywords

TriSalus Life Sciences, TriNav Infusion System, PEDD, nelitolimod, immunotherapy, liver cancer, pancreatic cancer, drug delivery, interventional radiology, oncology, clinical trials, FDA approval, medical device, biotechnology, pharmaceutical, SEPA, OrbiMed, warrant exchange, DELIVER program, CMS reimbursement